Lichen sclerosus: Evidence that immunological changes occur at all levels of the skin

British Journal of Dermatology

Volumn 140, Issue 6, 1999, Pages 1087-1092

  Farrell, A M ^a   Marren, P ^a   Dean, D ^a   Wojnarowska, F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

CD44 marker; Immunohistochemistry; Lichen sclerosus

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; HERMES ANTIGEN; HLA DR ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INFLAMMATORY INFILTRATE; LICHEN SCLEROSUS ET ATROPHICUS; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; LICHEN SCLEROSUS ET ATROPHICUS; MACROPHAGES; MIDDLE AGED; PROTEIN ISOFORMS; SKIN; VULVAR DISEASES;

EID: 0033057994     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02909.x     Document Type: Article

References (20)

1. 1 Walkden V, Chia Y, Wojnarowska F. The association of squamous cell carcinoma of the vulva and lichen sclerosus: implications for management and follow up. J Obstet Gynaecol 1997; 17: 551-3.
2. 2 Friedrich E, Kalra P. Serum levels of sex hormones in vulvar lichen sclerosus and the effect of topical testosterone, N Engl J Med 1984; 310: 488-91.
3. 3 Meyrick Thomas RH, Ridley C, McGibbon D. Black M. Lichen sclerosus et atrophicus and autoimmunity, a study of 350 women. Br J Dermatol 1988; 118: 41-6.
4. 4 Harrington CI. Dunsmore IR. An investigation into the incidence of autoimmune disorders in patients with lichen sclerosus et atrophicus. Br J Dermatol 1981; 104: 563-6.
5. 5 Dickie RJ. Horne C. Sutherland H et al. Direct evidence of localised immunological damage in vulvar lichen sclerosus et atrophicus. J Clin Pathol 1982; 35: 1395-7.
6. 6 Marren P. Welsh K. Wojnarowska F. The immunogenetic basis for lichen sclerosus. Br J Dermatol 1995; 132: 197-203.
7. 7 Underhill C. CD44: the hyaluron receptor. J Cell Sci 1992; 103: 293-8.
8. 8 Gunthert U, Stauder R. Mayer B et al. Are CD44 variants involved in human tumour progression? Cancer Surv 1995; 24: 19-42.
9. 9 Screaton GR, Bell MV, Jackson DG et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-4.
10. 10 Guttinger M, Sutti F, Barnier C. Expression of CD44 standard and variant forms in skin tumours. Loss of CD44 correlates with aggressive potential. Eur J Dermatol 1995; 5: 398-406.
11. 11 Carli P, Cattaneo A, Pimpinelli N et al. Immunohistochemical evidence of skin immune system involvement in vulvar lichen sclerosus et atrophicus. Dermatologica 1991; 182: 18-22.
12. 12 Carli P, Bracco G, Taddei G et al. Vulvar lichen sclerosus: immunohistologic evaluation before and after therapy. J Reprod Med 1994; 39: 110-14.
13. 13 Aubock J, Romani N, Grubauer G. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol 1986; 114: 465-72.
14. 14 Venning VA, Dean D, Wojnarowska F. Absence of expression of class II major histocompatibility complex determinants on keratinocytes in bullous pemphigoid. Br J Dermatol 1992; 126: 463-7.
15. 15 Basham T, Nickoloff B, Merigan T. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984; 83: 88-90.
16. 16 Marren P, Millard PR, Wojnarowska F. Vulval lichen sclerosus: lack of correlation between duration of clinical symptoms and histological appearances. J Eur Acad Dermatol Venereol 1997; 8: 212-16.
17. 17 Marren P, Charnock M, Wojnarowska F. Basement membrane zone in lichen sclerosus: an immunohistochemical study. Br J Dermatol 1997; 136: 508-14.
18. 18 Horst E, Meijer CJLM, Radaszkiewicz T et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-I (CD11a/18), and ICAM-1 (CD54). Leukemia 1990; 4: 595-9.
19. 19 Herrlich P, Zöller M, Pals ST, Ponta H. CD44 variants: metastases meet lymphocytes. Immunol Today 1993; 14: 395-9.
20. 20 Bennett KL, Jackson DG, Simon JC et al. CD44 isoforms containing cxon V3 are responsible for the presentation of heparin binding growth factor. J Cell Biol 1995; 128: 687-98.